PharmaCyte Biotech, Inc. (PMCB) Announces 1-for-19 Reverse Split
PharmaCyte Biotech (PMCB) approved a 1-for-19 reverse stock split, effective November 12, 2026. Outstanding shares will decrease from 10.8M to 566.1K. The split aims to meet Nasdaq's minimum bid-price requirement.
How this was made
The 30-second read
Why it matters
The split aims to restore Nasdaq compliance, which could improve liquidity and investor perception.
Market read
The announcement may affect microcap biotech investors and Nasdaq compliance monitoring.
What to watch
Potential dilution from future capital raises if compliance is not achieved.
Background
Reverse splits are used by low-priced stocks to meet exchange listing standards.
Ticker impact
PharmaCyte Biotech announced a 1-for-19 reverse split to regain Nasdaq minimum bid-price compliance.
likely downward pressure as investors adjust positions before the split, with possible stabilization after split-adjusted trading begins.
Corporate actions of this nature often cause short-term volatility; the primary catalyst is compliance restoration.
Market effects
May signal compliance pressure for other small-cap Nasdaq issuers.
Limited to US microcap biotech segment.
Minimal global impact.
Counterpoint
If the split fails to lift the price above $1, the stock could face delisting risk, presenting a short opportunity.
Key entities
- CompanyPharmaCyte Biotech, Inc.
Biotech firm listed on Nasdaq under ticker PMCB.
